Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Urinary Bladder Neoplasms 2Rectal Neoplasms 2Neoplasms 2Stomach Neoplasms 1Post-operative Ileus 1Pancreatic Neoplasms 1Pancreatic Cyst 1Lung Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Disease 1Colorectal Neoplasms 1Colonic Polyps 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Advanced Gastric Carcinoma 1

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Capecitabine 222Letrozole 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 133Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × Defecation × Clear all
NCT05444647 2022-07-06

Gut Microbiome Components Predict Response to Neoadjuvant Therapy in HER2-positive Breast Cancer Patients : A Prospective Study

The First Affiliated Hospital with Nanjing Medical University

Unknown
100 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡